MetLife Investment Management
PRME icon

MetLife Investment Management’s Prime Medicine PRME Stock Holding History

MetLife Investment Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
56,192
+11,984
+27% +$39.8K ﹤0.01% 2400
2026
Q1 		$154K Sell
44,208
-13,362
-23% -$50.9K ﹤0.01% 2344
2025
Q4 		$200K Buy
57,570
+14,573
+34% +$64.8K ﹤0.01% 2273
2025
Q3 		$238K Buy
42,997
+3,983
+10% +$16.2K ﹤0.01% 2220
2025
Q2 		$96.4K Buy
+39,014
New +$60.1K ﹤0.01% 2560
2025
Q1 		– Sell
-25,031
Closed -$73.1K – 2818
2024
Q4 		$73.1K Sell
25,031
-9,097
-27% -$31.9K ﹤0.01% 2702
2024
Q3 		$132K Hold
34,128
– – ﹤0.01% 2508
2024
Q2 		$175K Buy
34,128
+12,866
+61% +$78K ﹤0.01% 2332
2024
Q1 		$149K Hold
21,262
– – ﹤0.01% 2350
2023
Q4 		$188K Hold
21,262
– – ﹤0.01% 2273
2023
Q3 		$203K Hold
21,262
– – ﹤0.01% 2199
2023
Q2 		$311K Buy
21,262
+15,171
+249% +$212K ﹤0.01% 1992
2023
Q1 		$74.9K Hold
6,091
– – ﹤0.01% 2656
2022
Q4 		$113K Buy
+6,091
New +$110K ﹤0.01% 2543

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

MetLife Investment Management's PRME Position: Q2 2026 in Review

MetLife Investment Management increased its Prime Medicine (PRME) stake by 27% in Q2 2026, buying an estimated $39.8K and bringing the position to 56,192 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

MetLife Investment Management first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $311K in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • MetLife Investment Management held 56,192 shares of Prime Medicine worth $207K as of Q2 2026.
  • MetLife Investment Management bought 11,984 Prime Medicine shares in Q2 2026, an estimated $39.8K.
  • Prime Medicine made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2400 holding.
  • MetLife Investment Management first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • MetLife Investment Management's Prime Medicine position peaked at $311K in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.